Aptose Biosciences, Inc. (APTO)
| Market Cap | 185.90M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -55.74M |
| Shares Out | 88.95M |
| EPS (ttm) | -0.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 428,953 |
| Open | 2.08 |
| Previous Close | 2.08 |
| Day's Range | 2.06 - 2.15 |
| 52-Week Range | 1.96 - 7.20 |
| Beta | 1.25 |
| Analysts | Strong Buy |
| Price Target | 11.29 (+440.2%) |
| Earnings Date | Nov 11, 2021 |
About APTO
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the t...
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for APTO stock is "Strong Buy." The 12-month stock price forecast is 11.29, which is an increase of 440.19% from the latest price.
News
Aptose to Hold Corporate Update Monday, December 13th
HM43239 clinical update in AML after oral presentation at 2021 ASH Annual Meeting Luxeptinib clinical update in AML and B-cell cancers
Implied Volatility Surging for Aptose Biosciences (APTO) Stock Options
Investors need to pay close attention to Aptose Biosciences (APTO) stock based on the movements in the options market lately.
Aptose to Present at the Piper Sandler 33rd Annual Healthcare Conference
SAN DIEGO and TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlyi...
Aptose Reports Results for the Third Quarter 2021
- Conference call and webcast at 5:00 pm ET today -
Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting
HM43239 Data Accepted for Oral Presentation; Data for Luxeptinib and APTO-253 Accepted for Poster Presentation HM43239 Data Accepted for Oral Presentation; Data for Luxeptinib and APTO-253 Accepted for ...
Aptose Enters into Exclusive Worldwide License Agreement with Hanmi Pharmaceutical for Clinical-Stage Myeloid Kinome ...
HM43239 delivers multiple complete responses (CRs) in diverse R/R AML patients
Aptose to Report Third Quarter 2021 Financial Results and Hold Conference Call on Thursday, November 11, 2021
SAN DIEGO and TORONTO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlyi...
Aptose Expands Senior Leadership Team
Janet Clennett, CPA, appointed Vice President, Finance
Aptose to Present at September Investor Conferences
SAN DIEGO and TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlyi...
Aptose Biosciences (APTO) Moves to Buy: Rationale Behind the Upgrade
Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aptose Biosciences (APTO) Loses 19.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Aptose Biosciences (APTO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings es...
Aptose Reports Results for the Second Quarter 2021
- Conference call and webcast at 5:00 pm EDT today -
Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021
SAN DIEGO and TORONTO, July 20, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlyi...
Aptose Biosciences Stock Tumbles As Luxeptinib Fails To Impress At EHA2021 Virtual Congress
Aptose Biosciences Inc (NASDAQ: APTO) highlighted data from its luxeptinib currently in two Phase 1 a/b trials - one in relapsed or refractory acute myeloid leukemia (AML) and another in relapsed or ref...
Aptose Presents Highlights from EHA During Corporate Update Event
SAN DIEGO and TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeut...
Biotech Penny Stocks To Watch For June 2021
These penny stocks are expecting to release key information this month. The post Biotech Penny Stocks To Watch For June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto...
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
SAN DIEGO and TORONTO, June 01, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeut...
Aptose to Hold Corporate Update Friday, June 11th
Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS
Is the Options Market Predicting a Spike in Aptose (APTO) Stock?
Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.
Aptose to Present at Upcoming Investor Conferences
SAN DIEGO and TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlyin...
Aptose Reports Results for the First Quarter 2021
- Conference call and webcast at 4:30 pm EDT today -
Aptose to Report First Quarter 2021 Financial Results and Hold Conference Call on Tuesday, May 4, 2021
SAN DIEGO and TORONTO, April 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underly...
Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference
SAN DIEGO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underly...
Aptose Biosciences Stock Trades Higher After Q4 Earnings: Technical Levels To Watch
Aptose Biosciences Inc. (NASDAQ: APTO) shares traded higher after the company's release of fourth-quarter results Tuesday. The stock gained 66.21% in Wednesday's regular session, closing at $6.10.
Why Aptose Biosciences Stock Is Skyrocketing Today
The company reported very encouraging results from an early-stage study.